OP
OPRX.O
—
NASDAQ
Online Services
OptimizeRx Corp
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
119,2M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
10,7 %
ROE
4,0 %
Net margin
4,7 %
Debt / equity
0,20
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-07-28
Ex-dividend
—
TR 1Y
—
About
OptimizeRx Corp provides digital solutions for healthcare marketing and patient engagement, generating revenue primarily through software subscriptions and services.
Business. OptimizeRx Corp (OPRX.O) is a technology company operating in the Online Services industry within the Software & IT Services sector. The firm generates revenue primarily through an advertising model, with key performance indicators including monthly active users, average revenue per user, and ad impressions. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Classification92 %
SectorTechnology
Business sectorSoftware & IT Services
IndustryOnline Services
Generated · model-assisted
Sell-side consensus
BUY7 analysts
6 buy1 hold0 sell
Avg 12m price target14,50
Analyst recommendations
7 analysts · consensus BuyBuy6
Hold1
Sell0
12-month price target
14,50
Consensus of sell-side coverage.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,2 %+1,6 %+2,4 %
Energy+1,2 %+5,3 %+1,4 %
Real Estate+0,7 %+4,1 %+0,8 %
Health Care+0,6 %−0,5 %+0,8 %
Consumer Discretionary+0,3 %+8,7 %+0,5 %
Information Technology · THIS SECTOR−0,3 %+6,5 %−0,1 %
Financials−0,3 %−4,5 %−0,1 %
Consumer Staples−1,0 %+3,0 %−0,8 %
Utilities−1,5 %−21,2 %−1,3 %
Industrials−1,7 %−2,3 %−1,6 %
Communication Services———
Developing storylines
No tracked sagas currently linked to OPRX.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-07-07
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Composite score97 / 100
Composite score 0-100 · Data quality 0,58
Data quality0,58 / 1.00
Synthesis
Business
OptimizeRx Corp (OPRX.O) is a technology company operating in the Online Services industry within the Software & IT Services sector. The firm generates revenue primarily through an advertising model, with key performance indicators including monthly active users, average revenue per user, and ad impressions. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Classification92 %
SectorTechnology
Business sectorSoftware & IT Services
IndustryOnline Services
AI synthesis
GENERATEDOptimizeRx Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.2, indicating limited leverage. The company holds $23.4 million in cash and equivalents, while long-term debt stands at $25.7 million, resulting in a net cash position of -$2.3 million. Free cash flow of $9.5 million supports operational flexibility, though liquidity risk remains moderate due to the net cash deficit.
Profitability metrics show a return on equity of 4% and return on assets of 2.9%, both below the industry median for health care technology firms. Gross margin of 67.3% (calculated as $73.6 million gross profit / $109.4 million revenue) is strong, but operating margin of 10.7% (calculated as $11.7 million operating income / $109.4 million revenue) suggests pressure from operating expenses. Net income of $5.1 million reflects a 4.7% margin, which is modest for a software-as-a-service business.
Revenue is concentrated in a single business segment, with no geographic diversification disclosed. The company operates entirely within the United States, exposing it to domestic regulatory and reimbursement risks. No material revenue is attributed to international markets or product lines.
Growth trajectory is mixed. Revenue of $109.4 million in the latest period shows a 12.3% year-over-year increase, but the outlook for the current fiscal year projects a 7.8% growth rate. For the next fiscal year, the company anticipates a 5.2% increase, driven by expansion in digital health partnerships and product enhancements.
Risk factors include moderate liquidity risk due to the net cash deficit and a low dilution potential, with no recent share issuance or shelf registration activity. The company has not adjusted its valuation multiples for extraordinary items, suggesting stable operations.
Recent events include a Q4 earnings call highlighting progress in onboarding new healthcare clients and a 10-K filing disclosing no material litigation or regulatory issues. Analysts have issued a mean price target of $14.50, with a strong buy recommendation from two of seven covering analysts.
Key takeaways
- OptimizeRx maintains a low debt load but faces liquidity risk due to a net cash deficit.
- Profitability metrics are below industry medians, with a 4.7% net margin.
- Revenue is concentrated in a single segment and domestic market.
- Analysts project a 7.8% revenue growth for the current fiscal year.
- Dilution risk is low, with no recent share issuance or shelf registration.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$6,35
Market cap
$97.2M
Enterprise valueⓘ
$99.5M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
5.3x
P / Bⓘ
0.8x
P / Tangible bookⓘ
0.8x
Tangible book
$128.3M
Net cashⓘ
-$2.3M
Current ratioⓘ
3.0
Debt / equityⓘ
0.2
ROAⓘ
2.9%
ROEⓘ
4.0%
Cash conversionⓘ
365.0%
CapEx / revenueⓘ
0.1%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs OPRX · multiples and returns
GO
GOOG—
GOOG.O
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
GO
GOOGL—
ALPHABET INC.
$365,41
4,47T USDP/E
69,6x
+50,7 vs self
Div yield
0,2 %
— vs self
ROE
13,1 %
+9,1 vs self
ME
META—
META PLATFORMS, INC.
$594,16
1,52T USDP/E
56,2x
+37,2 vs self
Div yield
0,4 %
— vs self
ROE
11,0 %
+7,0 vs self
BA
BABA—
Alibaba Group Holding
$97,45
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BB
BBAAY—
BBAAY.PK
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
PD
PDD—
PDD Holdings Inc.
$82,97
117,8B USDP/E
5,1x
-13,9 vs self
Div yield
—
— vs self
ROE
12,8 %
+8,8 vs self
UB
UBER—
UBER TECHNOLOGIES, INC.
$69,69
141,9B USDP/E
—
— vs self
Div yield
0,0 %
— vs self
ROE
-5,9 %
-9,9 vs self
NF
NFLX—
NETFLIX, INC.
$76,77
323,3B USDP/E
184,0x
+165,0 vs self
Div yield
—
— vs self
ROE
9,7 %
+5,7 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 57 %
EPS
Consensus EPS
0,94
Predicted surprise
+0,04
Beat probability
57 %
Analysts
7
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,94 |
| Revenue | —no estimate | —no estimate | 111,4M USD |
| Operating income | —no estimate | —no estimate | 11,8M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-07-07
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution7 analysts
Strong buy2
Buy4
Hold1
Sell0
Strong sell0
12-month price target$14,50 · Median $14,00
Low $10,00High $20,00
Operating income · consensus11,8M USD
EPS surprise
+11,5 %
reported vs consensus · beat
Revenue surprise
−1,8 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$10,00
Mean$14,50
Median$14,00
High$20,00
Spot$6,35
+128.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin10,7 %Above median
Net Margin4,7 %Above median
ROE4,0 %Above median
Capex / Rev0,1 %Above P75
D/E0,20Below median
Cash Conv3,65Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 762 sh5 exercises · 1 grants5 insiders
- Chief Legal & Admin Officer · Restricted Stock Units → Common StockDisposed 4 000exercise · 2026-02-11
- Chief Finance & Strat Officer · Restricted Stock Units → Common StockDisposed 5 237exercise · 2025-12-19
- Chief Executive Officer · Restricted Stock Units → Common StockDisposed 6 546exercise · 2025-12-19
- Chief Legal & Admin Officer · Restricted Stock Units → Common StockDisposed 3 928exercise · 2025-12-19
- Chief Product & Tech Officer · Restricted Stock Units → Common StockDisposed 1 964exercise · 2025-12-19
- CHIEF OPERATING OFFICER · Stock Option → Common StockAcquired 23 437 @ $16,14grant · 2025-08-21
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- OptimizeRx Corp Market data — financials · 2026-05-28
- OptimizeRx Corp Market data — analyst estimates · 2026-05-28
- OptimizeRx Corp Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-06-300,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$14M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 1 sellsnet -$19K13 insiders · last 365d
- Director · Common StockOther 34 517 · 2026-06-09
- Director · Common StockOther 17 258 · 2026-06-09
- Director · Common StockOther 34 517 · 2026-06-09
- Director · Common StockOther 34 517 · 2026-06-09
- Director · Common StockOther 34 517 · 2026-06-09
- Director · Common StockOther 34 517 · 2026-06-09
- Chief Commercial Officer · Common StockOther 879 @ $5,21$5K · 2026-05-15
- Chief Commercial Officer · Common StockOther 914 @ $5,21$5K · 2026-05-15
- Chief Executive Officer · Common StockOther 5 219 @ $5,21$27K · 2026-05-15
- Director · Common StockOther 13 060 · 2026-05-01
- Chief Legal & Admin Officer · Common StockOther 4 000 · 2026-02-11
- Chief Legal & Admin Officer · Common StockOther 1 386 @ $9,23$13K · 2026-02-11
- Chief Product & Tech Officer · Common StockOther 4 079 @ $12,74$52K · 2025-12-23
- Chief Commercial Officer · Common StockOther 1 420 @ $12,74$18K · 2025-12-23
- Chief Executive Officer · Common StockOther 3 361 @ $12,74$43K · 2025-12-23
- Chief Legal & Admin Officer · Common StockOther 4 051 @ $12,74$52K · 2025-12-23
- Chief Finance & Strat Officer · Common StockOther 3 658 @ $12,74$47K · 2025-12-23
- Chief Finance & Strat Officer · Common StockOther 5 237 · 2025-12-19
- Chief Finance & Strat Officer · Common StockSold 1 388 @ $13,51$19K · 2025-12-19
- Chief Executive Officer · Common StockOther 6 546 · 2025-12-19
- Chief Executive Officer · Common StockOther 1 594 @ $13,51$22K · 2025-12-19
- Chief Legal & Admin Officer · Common StockOther 3 928 · 2025-12-19
- Chief Legal & Admin Officer · Common StockOther 1 153 @ $13,51$16K · 2025-12-19
- CHIEF OPERATING OFFICER · Common StockOther 289 @ $13,51$4K · 2025-12-19
- Chief Business Officer · Common StockOther 703 @ $13,51$9K · 2025-12-19
Short positioning
1.9Mshares short+7.0% vs prior
6.33days to cover
70.4%short of daily vol
1.2Kfails-to-deliver
as of 2026-06-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
OPRX.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Evidence & claims
From filings & derived data- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -23.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 125.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -10.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 124.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 9.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 74.6%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -48.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 185.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
- Gross margin (FY 2025-12-31): 67.3%Derived (calculated)
- Return on equity (FY 2025-12-31): 4.0%Derived (calculated)
- Return on assets (FY 2025-12-31): 2.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 125.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 9.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.04xDerived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 23.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 282.8%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.38xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 18.8%Derived (calculated)
- Net margin (FY 2025-12-31): 4.7%Derived (calculated)
- Capex (annual): USD 58KSEC XBRL filing
- Shares outstanding (annual): 18.76MSEC XBRL filing
- Cost of revenue (annual): USD 35.83MSEC XBRL filing
- Total operating expenses (annual): USD 61.9MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-09 00:00 UTCINSIDER6 insider transactions — 2026-06
2026-06-09INSIDERKLEMA CATHY transacted 34.5k sh — Director
2026-06-09INSIDERPresti Mariyamma Varghese transacted 17.3k sh — Director
2026-06-09INSIDERSpangler Patrick D transacted 34.5k sh — Director
2026-06-09INSIDERLang James Paul transacted 34.5k sh — Director
2026-06-09INSIDERVos Ellen O'Connor transacted 34.5k sh — Director
2026-06-09INSIDERWASSON GREGORY D transacted 34.5k sh — Director
2026-05-15 00:00 UTCINSIDER4 insider transactions — 2026-05
2026-05-15INSIDERGreco Theresa transacted 879 sh — Chief Commercial Officer ~$5k
2026-05-15INSIDERGreco Theresa transacted 914 sh — Chief Commercial Officer ~$5k
2026-05-15INSIDERSilvestro Stephen L transacted 5.2k sh — Chief Executive Officer ~$27k
2026-05-01INSIDERPresti Mariyamma Varghese transacted 13.1k sh — Director
2026-02-11 00:00 UTCINSIDER3 insider transactions — 2026-02 1 derivative
2026-02-11INSIDEROdence-Ford Marion transacted 4.0k sh — Chief Legal & Admin Officer
2026-02-11INSIDEROdence-Ford Marion transacted 1.4k sh — Chief Legal & Admin Officer ~$13k
2026-02-11INSIDEROdence-Ford Marion disposed of 4.0k sh Restricted Stock Units — Chief Legal & Admin Officer
2025-12-23 00:00 UTCINSIDER21 insider transactions — 2025-12 · net sell $310k 4 derivative
2025-12-23INSIDERBesch Doug transacted 4.1k sh — Chief Product & Tech Officer ~$52k
2025-12-23INSIDERGreco Theresa transacted 1.4k sh — Chief Commercial Officer ~$18k
2025-12-23INSIDERSilvestro Stephen L transacted 3.4k sh — Chief Executive Officer ~$43k
2025-12-23INSIDEROdence-Ford Marion transacted 4.1k sh — Chief Legal & Admin Officer ~$52k
2025-12-23INSIDERStelmakh Edward transacted 3.7k sh — Chief Finance & Strat Officer ~$47k
2025-12-19INSIDERStelmakh Edward transacted 5.2k sh — Chief Finance & Strat Officer
2025-12-19INSIDERStelmakh Edward sold 1.4k sh — Chief Finance & Strat Officer ~$19k
2025-12-19INSIDERSilvestro Stephen L transacted 6.5k sh — Chief Executive Officer
2025-12-19INSIDERSilvestro Stephen L transacted 1.6k sh — Chief Executive Officer ~$22k
2025-12-19INSIDEROdence-Ford Marion transacted 3.9k sh — Chief Legal & Admin Officer
2025-12-19INSIDEROdence-Ford Marion transacted 1.2k sh — Chief Legal & Admin Officer ~$16k
Showing the 40 most recent of 52 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-07
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage